GeneDx (WGS) Revenue & Revenue Breakdown
GeneDx Revenue Highlights
Latest Revenue (Y)
$202.57M
Latest Revenue (Q)
$76.87M
Main Segment (Y)
Diagnostic Test
GeneDx Revenue by Period
GeneDx Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $202.57M | -13.69% |
2022-12-31 | $234.69M | 10.60% |
2021-12-31 | $212.19M | 18.33% |
2020-12-31 | $179.32M | -8.59% |
2019-12-31 | $196.17M | - |
GeneDx Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | $76.87M | 9.02% |
2024-06-30 | $70.51M | 12.96% |
2024-03-31 | $62.42M | 8.72% |
2023-12-31 | $57.42M | 7.72% |
2023-09-30 | $53.30M | 9.44% |
2023-06-30 | $48.71M | 12.90% |
2023-03-31 | $43.14M | -29.68% |
2022-12-31 | $61.35M | -26.29% |
2022-09-30 | $83.23M | 130.13% |
2022-06-30 | $36.17M | -32.95% |
2022-03-31 | $53.94M | -6.68% |
2021-12-31 | $57.80M | 33.87% |
2021-09-30 | $43.18M | -7.87% |
2021-06-30 | $46.87M | -27.00% |
2021-03-31 | $64.20M | 0.38% |
2020-12-31 | $63.96M | 65.66% |
2020-09-30 | $38.61M | - |
GeneDx Revenue Breakdown
GeneDx Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 22 |
---|---|
Product and Service, Other | $7.36M |
Diagnostic Test | $227.33M |
Latest
Quarterly Revenue by Product
Product/Service | Sep 24 | Jun 24 |
---|---|---|
Diagnostic Test, Institutional Customers | $17.41M | $16.70M |
Diagnostic Test, Self Pay | $460.00K | $692.00K |
Diagnostic Test, Third Party Insurance | $59.54M | $52.05M |
Product and Service, Other | $-544.00K | $1.07M |
Diagnostic Test | $77.42M | $69.44M |
Latest
GeneDx Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
PRVA | Privia Health Group | $1.66B | $422.33M |
CERT | Certara | $354.34M | $94.82M |
HSTM | HealthStream | $279.06M | $73.09M |
DH | Definitive Healthcare | $251.41M | $62.70M |
WGS | GeneDx | $202.57M | $76.87M |
NRC | National Research | $148.58M | $35.82M |
HCTI | Healthcare Triangle | $33.20M | $2.41M |
EUDA | EUDA Health | $3.71M | $1.11M |
ACON | Aclarion | $75.40K | $10.97K |